Yannis Sainte-Marie

Yannis Sainte-Marie

Auto-generated profile, based on publicly available information

Yannis Sainte-Marie

Institute of Metabolic and Cardiovascular Diseases, INSERM/Paul Sabatier University, UMR1297, Team MetaDiab, Toulouse, France

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2005 in Circulation
Verified
Journal Article
Closed access
PDF file
AOAntoine Ouvrard-Pascaud
Antoine Ouvrard-Pascaud
YSYannis Sainte-Marie
Yannis Sainte-Marie
Jean-Pierre BenitahJean-Pierre Benitah
Jean-Pierre Benitah
RPRomain Perrier
Romain Perrier
CSChristelle Soukaseum
Christelle Soukaseum
FJFrédéric Jaisser
Frédéric Jaisser
Background— Life-threatening cardiac arrhythmia is a major source of mortality worldwide. Besides rare inherited monogenic diseases such as long-QT or Brugada syndromes, which reflect abnormalities in ion fluxes across cardiac ion channels as a final common pathway, arrhythmias are most frequently acquired and associated with heart disease. The mineralocorticoid hormone aldosterone is an important contributor to morbidity and mortality in heart failure, but its mechanisms of action are incompletely understood. Methods and Results— To specifically assess the role of the mineralocorticoid receptor (MR) in the heart, in the absence of changes in aldosteronemia, we generated a transgenic mouse model with conditional cardiac-specific overexpression of the human MR. Mice exhibit a high rate of death prevented by spironolactone, an MR antagonist used in human therapy. Cardiac MR overexpression led to ion channel remodeling, resulting in prolonged ventricular repolarization at both the cellular and integrated levels and in severe ventricular arrhythmias. Conclusions— Our results indicate that cardiac MR triggers cardiac arrhythmias, suggesting novel opportunities for prevention of arrhythmia-related sudden death.

1 July 2012 in Gastroenterology
Verified
Journal Article
Closed access
PRPierre–Emmanuel Rautou
Pierre–Emmanuel Rautou
JBJulie Bresson
Julie Bresson
YSYannis Sainte–Marie
Yannis Sainte–Marie
AVAnne–Clemence Vion
Anne–Clemence Vion
VPValerie Paradis
Valerie Paradis
CBChantal M. Boulanger
Chantal M. Boulanger

17 February 2017 in Circulation Research
Verified
Journal Article
Closed access
PDF file
LFLoubina Fazal
Loubina Fazal
MLMarion Laudette
Marion Laudette
SPSílvia Paula-Gomes
Sílvia Paula-Gomes
SPSandrine Pons
Sandrine Pons
CCCaroline Conte
Caroline Conte
Frank Lezoualc'hFrank Lezoualc'h
Frank Lezoualc'h
Rationale:: Although the second messenger cyclic AMP (cAMP) is physiologically beneficial in the heart, it largely contributes to cardiac disease progression when dysregulated. Current evidence suggests that cAMP is produced within mitochondria. However, mitochondrial cAMP signaling and its involvement in cardiac pathophysiology are far from being understood. Objective:: To investigate the role of MitEpac1 (mitochondrial exchange protein directly activated by cAMP 1) in ischemia/reperfusion injury. Methods and Results:: We show that Epac1 (exchange protein directly activated by cAMP 1) genetic ablation ( Epac1 −/− ) protects against experimental myocardial ischemia/reperfusion injury with reduced infarct size and cardiomyocyte apoptosis. As observed in vivo, Epac1 inhibition prevents hypoxia/reoxygenation–induced adult cardiomyocyte apoptosis. Interestingly, a deleted form of Epac1 in its mitochondrial-targeting sequence protects against hypoxia/reoxygenation–induced cell death. Mechanistically, Epac1 favors Ca 2+ exchange between the endoplasmic reticulum and the mitochondrion, by increasing interaction with a macromolecular complex composed of the VDAC1 (voltage-dependent anion channel 1), the GRP75 (chaperone glucose-regulated protein 75), and the IP3R1 (inositol-1,4,5-triphosphate receptor 1), leading to mitochondrial Ca 2+ overload and opening of the mitochondrial permeability transition pore. In addition, our findings demonstrate that MitEpac1 inhibits isocitrate dehydrogenase 2 via the mitochondrial recruitment of CaMKII (Ca 2+ /calmodulin-dependent protein kinase II), which decreases nicotinamide adenine dinucleotide phosphate hydrogen synthesis, thereby, reducing the antioxidant capabilities of the cardiomyocyte. Conclusions:: Our results reveal the existence, within mitochondria, of different cAMP–Epac1 microdomains that control myocardial cell death. In addition, our findings suggest Epac1 as a promising target for the treatment of ischemia-induced myocardial damage.

28 April 2009 in Circulation
Verified
Journal Article
Closed access
AGAna María GómEz
Ana María GómEz
Angélica RuedaAngélica Rueda
Angélica Rueda
YSYannis Sainte-Marie
Yannis Sainte-Marie
LPLaetitia Pereira
Laetitia Pereira
SZSpyros Zissimopoulos
Spyros Zissimopoulos
Jean-Pierre BenitahJean-Pierre Benitah
Jean-Pierre Benitah
Background— The mineralocorticoid pathway is involved in cardiac arrhythmias associated with heart failure through mechanisms that are incompletely understood. Defective regulation of the cardiac ryanodine receptor (RyR) is an important cause of the initiation of arrhythmias. Here, we examined whether the aldosterone pathway might modulate RyR function. Methods and Results— Using the whole-cell patch clamp method, we observed an increase in the occurrence of delayed afterdepolarizations during action potential recordings in isolated adult rat ventricular myocytes exposed for 48 hours to aldosterone 100 nmol/L, in freshly isolated myocytes from transgenic mice with human mineralocorticoid receptor expression in the heart, and in wild-type littermates treated with aldosterone. Sarcoplasmic reticulum Ca 2+ load and RyR expression were not altered; however, RyR activity, visualized in situ by confocal microscopy, was increased in all cells, as evidenced by an increased occurrence and redistribution to long-lasting and broader populations of spontaneous Ca 2+ sparks. These changes were associated with downregulation of FK506-binding proteins (FKBP12 and 12.6), regulatory proteins of the RyR macromolecular complex. Conclusions— We suggest that in addition to modulation of Ca 2+ influx, overstimulation of the cardiac mineralocorticoid pathway in the heart might be a major upstream factor for aberrant Ca 2+ release during diastole, which contributes to cardiac arrhythmia in heart failure.

19 November 2014 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
ALAnne-Coline Laurent
Anne-Coline Laurent
Malik BisserierMalik Bisserier
Malik Bisserier
ALAlexandre Lucas
Alexandre Lucas
FTFlorence Tortosa
Florence Tortosa
MRMarie Roumieux
Marie Roumieux
Frank Lezoualc'hFrank Lezoualc'h
Frank Lezoualc'h
Stimulation of β-adrenergic receptors (β-AR) increases cAMP production and contributes to the pathogenesis of cardiac hypertrophy and failure through poorly understood mechanisms. We previously demonstrated that Exchange protein directly activated by cAMP 1 (Epac1)-induced hypertrophy in primary cardiomyocytes. Among the mechanisms triggered by cardiac stress, autophagy has been highlighted as a protective or harmful response. Here, we investigate whether Epac1 promotes cardiac autophagy and how altered autophagy has an impact on Epac1-induced cardiomyocyte hypertrophy. We reported that direct stimulation of Epac1 with the agonist, Sp-8-(4-chlorophenylthio)-2′-O-methyl-cAMP (Sp-8-pCPT) promoted autophagy activation in neonatal cardiomyocytes. Stimulation of β-AR with isoprenaline (ISO) mimicked the effect of Epac1 on autophagy markers. Conversely, the induction of autophagy flux following ISO treatment was prevented in cardiomyocytes pre-treated with a selective inhibitor of Epac1, CE3F4. Importantly, we found that Epac1 deletion in mice protected against β-AR-induced cardiac remodelling and prevented the induction of autophagy. The signalling mechanisms underlying Epac1-induced autophagy involved a Ca2+/calmodulin-dependent kinase kinase β (CaMKKβ)/AMP-dependent protein kinase (AMPK) pathway. Finally, we provided evidence that pharmacological inhibition of autophagy using 3-methyladenine (3-MA) or down-regulation of autophagy-related protein 5 (Atg5) significantly potentiated Epac1-promoted cardiomyocyte hypertrophy. Altogether, these findings demonstrate that autophagy is an adaptive response to antagonize Epac1-promoted cardiomyocyte hypertrophy.

1 September 2007 in The American Journal of Pathology
Verified
Journal Article
Closed access
YMYannis Sainte Marie
Yannis Sainte Marie
ATAntoine Toulon
Antoine Toulon
RPRalf Paus
Ralf Paus
EMEve Maubec
Eve Maubec
ACAicha Cherfa
Aicha Cherfa
FJFrédéric Jaisser
Frédéric Jaisser